Denali Therapeutics Inc. (NASDAQ:DNLI) Position Trimmed by Jane Street Group LLC

Jane Street Group LLC trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 37.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,165 shares of the company's stock after selling 137,906 shares during the period. Jane Street Group LLC owned about 0.16% of Denali Therapeutics worth $4,670,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DNLI. Sterling Capital Management LLC grew its holdings in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. PNC Financial Services Group Inc. raised its holdings in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the period. KBC Group NV raised its holdings in Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after buying an additional 2,731 shares during the period. AlphaQuest LLC raised its holdings in Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after buying an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. increased its holdings in Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on DNLI shares. HC Wainwright lowered their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. B. Riley restated a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Morgan Stanley initiated coverage on Denali Therapeutics in a report on Friday, March 7th. They issued an "overweight" rating and a $33.00 price target for the company. Wedbush decreased their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Trading Down 1.2%

NASDAQ:DNLI traded down $0.16 during midday trading on Friday, hitting $14.00. 171,279 shares of the stock were exchanged, compared to its average volume of 1,091,717. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -5.08 and a beta of 1.49. The business has a 50-day moving average price of $14.13 and a two-hundred day moving average price of $19.74.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the company earned ($0.68) earnings per share. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.